In Diligence, 60-80% of Life Sciences Deals Result in a "No-Go"
Common
VC Challenges
You see lots of promising Life Sciences companies early on.
But many CEOs are:
Not yet investor-ready.
Unclear on development milestones.
Lacking empirical evidence, proof of concept, and supporting data.
Weak on execution discipline.
Underprepared for diligence scrutiny.
Far away from clinical or commercial inflection points.
Have critical gaps in their team.
Lack of differentiation.
Runway & burn miscalculations.
So you pass — or wait.
Meanwhile, potential value stalls,
CEO relationships are strained, trust erodes.
What if there was a different approach?
Enter CEO360.
CEO360 for VCs
The CEO360 Solution
CEO360 Is The
"No-Go" Alternative
Most early-stage Life Sciences companies
don’t fail because of science.
They fail because leadership, execution discipline,
and capital readiness break down under diligence.
VCs are forced to mark high-potential investment opportunities
as “No-Go”, walk away and avoid unnecessary risk.
Over a structured
12-month journey, CEOs:
Mature leadership and governance discipline.
Strengthen technical and regulatory readiness.
Build defensible execution plans.
Align capital needs with value creation.
Close diligence gaps early.
Companies Improve Before VCs Invest.
VC Investors Refer CEOs and Then Return Quarterly
The CEO360
VC Observer Model
How It Works
You refer CEOs. CEOs enter structured execution sprints. You return quarterly to observe applied progress. Conviction builds through pattern recognition over time.
Progress Reviews
Refer us your high potential, not quite ready CEOs. Share your insights with CEO360. Check back in every 90 days. No fees, no financial obligation.
Why Investors Participate
CEO360 helps investors identify CEOs who execute under pressure. Investors maintain early visibility into promising companies and deploy capital with confidence.
Expected Time Commitment
Approximately four hours per quarter to observe CEO progress sessions, ask questions and provide feedback
Ideal CEO Referrals
CEO360 Is Best Suited
For CEOs Who:
Lead Small Molecule, Large Molecule and MedTech-BioTools companies.
Have promising science or technology.
Are not yet fully investable.
Are coachable and execution-focused.
The CEOs you like — just not quite ready.
Refer CEOs early.
Watch them become investable.